Tuberculosis vaccine may help protect against COVID-19
An observational study said that people who have had their BCG anti-tuberculosis vaccine were less vulnerable to symptoms of COVID19 and were less likely to have infection-fighting antibodies in their blood. Scientists developed the BCG vaccine over 100 years ago to protect against tuberculosis.
The evidence says that BCG protects adolescents and the elderly from acute respiratory infections caused by viruses. We are interested in studying the BCG vaccine because it has long been known that the BCG vaccine provides general protection against a variety of bacterial and viral diseases other than tuberculosis, including tuberculosis, including tuberculosis. Including neonatal sepsis and respiratory tract infections.
Between 11 May and 18 June 2020, 6,201 health workers took blood samples and answered questions about their medical history, including whether they received BCG and whether they were vaccinated against two other bacterial infections and influenza. In a nutshell, these results say that a history of BCG vaccination gives you a nonspecific protective effect against SARSCoV2 infection and reduces the appearance of Covid 19 symptoms.
In August 2020, another research showed that countries requiring BCG vaccination have developed more or less "herd immunity" against the disease. In a recent study, the Medical Research Council of India showed that a vaccine that has been used to treat tuberculosis for the past 100 years can help prevent the risk of COVID19 infection in older people. COVID19 Tuberculosis Vaccine - Learn all about the Bacillus Calmette Guerin vaccine, considered one of the most widely used vaccines in the world, with about 130 million babies every year.
Older people are increasingly interested in BCG vaccination, especially in countries with a high number of reported cases of COVID19. Previous studies have shown that the BCG vaccine can protect against respiratory and viral infections. This anti-tuberculosis vaccine may protect against inflammatory diseases. In addition, the study also showed that the recent BCG vaccination was not associated with hyper inflammation, but, on the contrary, with this disease. Basal inflammation is suppressed, which may play a protective role in the elderly against inflammatory disease. Therefore, this study emphasizes that the effects of BCG vaccination are safe and do not lead to increased inflammation in the elderly. The results of this study not only support regulatory properties. They also found the BCG vaccine to be immunogenic. clear specificity Researchers noted the immunogenic effect of BCG vaccine on systemic inflammation.
A better understanding of the results may support vaccine efficacy and explore the potential for more effective use of the BCG vaccine. Some people refer to TB as a "Forgotten Pandemic."
Perhaps the biggest difference in our responses to these pandemics is that we have many effective vaccines against Covid 19. For tuberculosis, we rely on one. The 100-year-old vaccine known as BCG is still one of them. The BCG vaccine, unlike the Covid vaccine, is a vaccine. Please live, which means it contains living bacteria. Maybe BCG and Covid vaccines will complete the cycle.
The BRACE trial, begun by the Murdoch Children's Research Institute in Melbourne, is investigating whether the BCG vaccine can protect against Covid infections. Regardless of whether BCG prevents Covid, there is no doubt that we need new and more effective TB vaccines. While we have a growing number of potential vaccine candidates, there is currently no alternative to our 100-year-old BCG. Global activity in the development of a Covid vaccine has also prompted calls for increased efforts and funding to develop a new TB vaccine.
The widely used anti-tuberculosis vaccine is associated with a lower likelihood of infection. This data suggests that the vaccine has been approved by the United States.The FDA can help prevent or reduce the severity of coronavirus infection.
In the United States, it is approved by the FDA as a drug for bladder cancer and as a vaccine for people at high risk of tuberculosis. The BCG vaccine is currently undergoing numerous clinical trials around the world to determine its effectiveness against COVID19.In a new study, lower antibody levels in the BCG group persisted although these people had higher rates of high blood pressure, diabetes, cardiovascular disease, and COPD, which are known risk factors. They are more susceptible to SARSCoV2 and develop to a greater extent. severe forms of COVID19. Several randomized clinical trials have been initiated to investigate the possible protective effects of the BCG vaccine against COVID19.
